TaiGen Biotechnology Starts China Trial Of Novel Chemotherapy Sensitizer
TaiGen Biotechnology of Taiwan has started a China clinical trial of burixafor, the company's novel stem cell mobilizer, which will be tested as a chemotherapy sensitizer. The Phase I/II trial will study burixafor in combination with two chemotherapy agents, fludaragine and cytarabine, in patients with relapsed or refractory acute myeloid leukemia. The drug has already completed a Phase IIa trial in the US.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.